Trials / Terminated
TerminatedNCT04176016
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- OncoTherapy Science, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous administration of OTSA101-DTPA-90Y.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTSA101-DTPA-111In | single IV injection, 185MBq/body |
| DRUG | OTSA101-DTPA-90Y | IV injection (max. 3 injections per patient), 1110MBq/body |
Timeline
- Start date
- 2020-01-10
- Primary completion
- 2024-01-11
- Completion
- 2024-01-11
- First posted
- 2019-11-25
- Last updated
- 2024-02-02
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04176016. Inclusion in this directory is not an endorsement.